Global Hunter Syndrome Treatment Market, By Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Hunter Syndrome Treatment Market Analysis and Size
According to the National Institute of Health 2018 report, frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Hunter syndrome is of two types, severe and mild. These both affect numerous different tissues and organs. Individuals with extreme case begin to lose basic functional skills between the age group of 6 and 8 years. The normal life expectancy of these people is 10 to 20 years.
Data Bridge Market Research analyses a growth rate in the Hunter syndrome treatment market in the forecast period 2023-2030. The expected CAGR of schistosomiasis diseases market is tend to be around 8.6% in the mentioned forecast period. The market was valued at USD 927.57 million in 2022, and it would grow up to USD 1794.67 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hunter Syndrome Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Medtronic (Ireland.), Abbott (U.S.), BD (U.S.), Johnson & Johnson Services, Inc., GSK Plc. (U.K.), Bayer AG (Germany), Zimmer Biomet (U.S.), Stryker Corporation (U.S.), Homology Medicines, Inc (U.S.), Novartis AG (Switzerland), Pfizer Inc.(U.S.), JCR Pharmaceuticals Co., Ltd.(Japan), Sangamo Therapeutics (U.S.), AVROBIO, Inc (U.S.), REGENXBIO Inc (U.S), CANbridge Life Sciences Ltd.(Taiwan)., Denali Therapeutics (U.S.), and Jasper Therapeutics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Hunter syndrome is a rare, inherited genetic disorder that is caused by missing or malfunctioning of enzyme, iduronate-2-sulfatase. Body does not properly digest or break down sugar molecules in the body. When these molecules build up in organs and tissues over the time, they can cause severe damage, affecting physical and mental development and abilities. The disorder commonly occurs in boys. The condition is one of a group of inherited metabolic disorders known as mucopolysaccharidosis (MPS).
Global Hunter Syndrome Treatment Market Dynamics
Drivers
- Growing Awareness about Hunter Syndrome
There is growing awareness about Hunter syndrome and the availability of varied therapeutic options may boost the revenue growth of the market. For instance, in 2018, Shire PLC, with International MPS Network and National MPS Society, launched the #FlyforMPS campaign to raise awareness about mucopolysaccharide diseases, and it is affecting at least one in 25000 births in the U.S.. Furthermore, a report was published by the National Institute of Health in 2018 states that, Hunter syndrome disease is affecting 1 in 160,000 males worldwide, making it a rare disease.
Opportunities
- Increasing number of research and development activities
The market growth is fuelled by an increase in the number of R&D activities. This will provide beneficial opportunities for the market growth. For instance, in 2017, Shire PLC announced top-line results from its Phase II/III clinical trial assessing SHP609, previously known as HGT-2310. It is an investigational formulation of idursulfase administered intrathecally for a new potential indication used for the treatment of pediatric patients suffering from hunter syndrome and cognitive impairment.
- Increased Funding For Drug Approvals and Processes
There has been increased funding for various drug launches and programs that are boosting the growth of the market. For instance, in 2017, research funded by the National Institute of Neurological Disorders and Stroke (NINDS) has shown that viral-delivered gene therapy can stop the build up materials that are stored in the brain cells and can help in improving memory and learning. In the recent years, health insurance coverage and numerous reimbursement policies for such costly drugs also prompting pharmaceutical companies to invest in drug development.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified healthcare professionals unable to perform these treatments could limit the growth of the market during the forecast period.
- High Cost
The huge expenditure that is required for the varied treatment processes hamper the market growth. Several market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.
This Hunter syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Hunter syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development:
- In January 2021, GC Pharma and Clinigen K.K. received Japanese manufacturing and marketing approval for Hunterase ICV (intracerebroventricular) Injection 15 mg for the treatment for mucopolysaccharidosis type II (Hunter syndrome)
- In September 2020, CANbridge Pharmaceuticals Inc. announced that it received marketing approval from China’s National Medical Products Administration (NMPA) for Hunterase (Idursulfase beta Injection), an enzyme replacement therapy (ERT) for the long-term treatment of patients with mucopolysaccharidosis II (MPS II or Hunter syndrome).
Global Hunter Syndrome Treatment Market Scope
The Hunter syndrome treatment market is segmented on the basis of severity, type, complications, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Severity
- Mild to Moderate
- Moderate to Severe
Type
- Enzyme Replacement Therapy (ERT)
- Stem Cell Transplant
- Surgical Treatment
- Others
Complications
- Respiratory Disorders
- Neurological Disorders
- Gastrointestinal Disorder
- Cardiovascular
- Ophthalmic
- Audiologic
- Dental
- Musculoskeletal
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Hunter Syndrome Treatment Market Regional Analysis/Insights
The Hunter syndrome treatment market is analyzed and market size insights and trends are provided by severity, type, complications, distribution channel and end-user as referenced above.
The major countries covered in the Hunter syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market due to the presence of key product manufacturers and increasing research and development activities.
Asia-Pacific is considered to grow over the coming years due to increasing investment in innovative R&D for novel treatment product.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hunter Syndrome Treatment Market Share Analysis
The Hunter syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Hunter syndrome treatment market
Key players operating in the Hunter syndrome treatment market include:
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Medtronic (Ireland.)
- Abbott (U.S.)
- BD (U.S.)
- Johnson & Johnson Services, Inc.(U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Zimmer Biomet (U.S.)
- Stryker Corporation (U.S.)
- Homology Medicines, Inc (U.S.)
- Novartis AG (Switzerland)
- Pfizer Inc.(U.S.)
- JCR Pharmaceuticals Co., Ltd. (Japan)
- Sangamo Therapeutics (U.S.)
- AVROBIO, Inc (U.S.)
- REGENXBIO Inc (U.S)
- CANbridge Life Sciences Ltd. (Taiwan)
- Denali Therapeutics (U.S.)
- Jasper Therapeutics, Inc. (U.S.)
SKU-